Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 6/20 | 0.76 |
| ▸ | MEN1 | O00255 | 1/20 | 0.76 |
| ▸ | ABL1 | P00519 | 1/20 | 0.76 |
| ▸ | LMNA | P02545 | 1/20 | 0.76 |
| ▸ | PKM | P14618 | 1/20 | 0.76 |
| ▸ | IDE | P14735 | 1/20 | 0.76 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.76 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.76 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.76 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.76 |
| ▸ | HLCS | P50747 | 6/20 | 0.71 |
| ▸ | CA12 | O43570 | 5/20 | 0.48 |
| ▸ | CA1 | P00915 | 5/20 | 0.48 |
| ▸ | CA2 | P00918 | 5/20 | 0.48 |
| ▸ | CA9 | Q16790 | 5/20 | 0.48 |
| ▸ | F2 | P00734 | 1/20 | 0.46 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.46 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.46 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.46 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Biotin SCHEMBL715457 | 0.99 | TDP1 (0.77) | TDP1MEN1ABL1LMNAPKM | |
| Biotin SCHEMBL3425472 | 0.94 | TDP1 (0.85) | TDP1MEN1ABL1LMNAPKM | |
| Biotin SCHEMBL770770 | 0.94 | TDP1 (0.85) | TDP1MEN1ABL1LMNAPKM | |
| Biotin SCHEMBL739967 | 0.94 | TDP1 (0.85) | TDP1MEN1ABL1LMNAPKM | |
| Biotin SCHEMBL16653090 | 0.93 | TDP1 (0.83) | TDP1MEN1ABL1LMNAPKM | |
| Stearic Acid SCHEMBL10828834 | 0.93 | TDP1 (0.83) | TDP1MEN1ABL1LMNAPKM | |
| Biotin SCHEMBL8651197 | 0.93 | TDP1 (0.87) | TDP1MEN1ABL1LMNAPKM | |
| Biotin SCHEMBL6033491 | 0.93 | TDP1 (0.87) | TDP1MEN1ABL1LMNAPKM | |
| Biotin SCHEMBL8672968 | 0.92 | TDP1 (0.85) | TDP1MEN1ABL1LMNAPKM | |
| Biotin SCHEMBL987288 | 0.91 | TDP1 (0.79) | TDP1MEN1ABL1LMNAPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11980613-B2 | Methods for reversing HIV latency using BAF complex modulating compounds | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2024-05-14 | — | — | US | disclosed |
| EP-3820460-A1 | METHODS FOR REVERSING HIV LATENCY USING BAF COMPLEX MODULATING COMPOUNDS | The Board of Trustees of the Leland Stanford Junior University (US) | 2021-05-19 | — | — | EP | disclosed |
| US-5747352-A | Reagents and methods for the rapid and quantitative assay of pharmacological agents | BECKMAN INSTRUMENTS, INC. (US) | 1998-05-05 | — | — | US | disclosed |
| EP-0710361-A1 | REAGENTS AND METHODS FOR THE RAPID AND QUANTITATIVE ASSAY OF PHARMACOLOGICAL AGENTS | BECKMAN INSTRUMENTS, INC. (US) | 1996-05-08 | — | — | EP | disclosed |
| WO-1995032428-A1 | REAGENTS AND METHODS FOR THE RAPID AND QUANTITATIVE ASSAY OF PHARMACOLOGICAL AGENTS | BECKMAN INSTRUMENTS, INC. (US) | 1995-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11980613-B2 | Methods for reversing HIV latency using BAF complex modulating compounds | CHD1L, SMARCC1, CHD1 | TDP1 1722/4885MEN1 3742/4885ABL1 4368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.